- Home
- KEY vs BIIB Comparison
KEY vs BIIB Comparison
Compare KEY & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KEY
- BIIB
- Stock Information
- Founded
- KEY 1825
- BIIB 1978
- Country
- KEY United States
- BIIB United States
- Employees
- KEY N/A
- BIIB N/A
- Industry
- KEY Major Banks
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- KEY Finance
- BIIB Health Care
- Exchange
- KEY Nasdaq
- BIIB Nasdaq
- Market Cap
- KEY 17.3B
- BIIB 18.8B
- IPO Year
- KEY N/A
- BIIB 1991
- Fundamental
- Price
- KEY $18.51
- BIIB $132.82
- Analyst Decision
- KEY Buy
- BIIB Buy
- Analyst Count
- KEY 18
- BIIB 27
- Target Price
- KEY $19.19
- BIIB $188.17
- AVG Volume (30 Days)
- KEY 14.1M
- BIIB 1.3M
- Earning Date
- KEY 07-21-2025
- BIIB 07-31-2025
- Dividend Yield
- KEY 4.44%
- BIIB N/A
- EPS Growth
- KEY N/A
- BIIB 26.39
- EPS
- KEY N/A
- BIIB 10.12
- Revenue
- KEY $4,464,000,000.00
- BIIB $9,816,400,000.00
- Revenue This Year
- KEY $75.04
- BIIB N/A
- Revenue Next Year
- KEY $6.51
- BIIB N/A
- P/E Ratio
- KEY N/A
- BIIB $13.13
- Revenue Growth
- KEY N/A
- BIIB 1.59
- 52 Week Low
- KEY $12.73
- BIIB $110.04
- 52 Week High
- KEY $20.04
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- KEY 79.74
- BIIB 59.57
- Support Level
- KEY $16.01
- BIIB $123.90
- Resistance Level
- KEY $16.89
- BIIB $134.75
- Average True Range (ATR)
- KEY 0.34
- BIIB 3.50
- MACD
- KEY 0.21
- BIIB 0.28
- Stochastic Oscillator
- KEY 96.96
- BIIB 83.71
About KEY KeyCorp
With assets of over $185 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.